Novacyt S.A.
Novacyt S.A. (NVYTF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nvytf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Novacyt S.A.You NVYTF | $35M | N/A | — | — |
 The Cannabist Company Holdings Inc. CBSTF | $14M | N/A | — | -$0.23 |
 Drug Free Solution, Inc. DSOL | $0M | N/A | — | -$0.00 |
 Nova Eye Medical Limited ELXMF | $1M | N/A | — | -$0.04 |
 ImpediMed Limited IPDQF | $11M | N/A | — | -$0.01 |
 iAnthus Capital Holdings, Inc. ITHUF | $32M | N/A | — | -$0.01 |
 Medical Developments International Limited MDDVF | $34M | 608.90x | — | $0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Novacyt S.A. (NVYTF) measures how much investors pay for each dollar of the company's trailing earnings. NVYTF's current PE ratio of N/A is calculated by dividing its stock price of $0.48 by its TTM earnings per share of —.
Frequently asked questions
NVYTF pe ratio · 6 questionsNVYTF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.48 and TTM EPS of —. Data sourced from Financial Modeling Prep via NVYTF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Novacyt S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09